SAM #36C26127N0063

VA award for Novartis PLUVICTO treatments for Palo Alto

The Department of Veterans Affairs awarded a requirement for PLUVICTO treatments for Veterans served by the Palo Alto VA Health Care System. - Government buyer: Department of Veterans Affairs, VISN 5, Health Service Area 52, Regional Procurement Office West, Network Contracting Office 21, on behalf of VA Palo Alto Health Care System. - Award: $4,115,311.20. - OEM and product: Novartis Pharmaceuticals Corporation’s PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), NDC 69488-0010-61. - Quantity: 54 treatments, with an option for 36 additional treatments. The justification also references an estimated quantity of 120 doses; the documents do not reconcile these quantities. - Intended use: targeted radiopharmaceutical therapy for adult Veterans with PSMA-positive metastatic castration-resistant prostate cancer. Each Veteran requires six treatment cycles administered every six weeks. - Notable requirement: the justification identifies the VA National Acquisition Center contract and Novartis as the only listed source for the required NDC.

Description

Awardee: NOVARTIS PHARMACEUTICALS CORPORATION

Award Amount: $4,115,311.20

Period of Performance: 10/1/2026 - 09/30/2027

Limited Source Justification Attached

View original listing